vs
Orthofix Medical Inc.（OFIX）与SIMMONS FIRST NATIONAL CORP（SFNC）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是SIMMONS FIRST NATIONAL CORP的1.1倍（$219.9M vs $197.3M），SIMMONS FIRST NATIONAL CORP同比增速更快（19.6% vs 2.0%），SIMMONS FIRST NATIONAL CORP自由现金流更多（$411.4M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 0.6%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
西蒙斯第一国民公司是一家银行控股企业，旗下核心子公司西蒙斯银行的业务覆盖阿肯色州、堪萨斯州、密苏里州、俄克拉荷马州、田纳西州及得克萨斯州，为当地客户提供各类银行相关金融服务。
OFIX vs SFNC — 直观对比
营收规模更大
OFIX
是对方的1.1倍
$197.3M
营收增速更快
SFNC
高出17.6%
2.0%
自由现金流更多
SFNC
多$394.5M
$16.8M
两年增速更快
OFIX
近两年复合增速
0.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $197.3M |
| 净利润 | $-2.2M | — |
| 毛利率 | 71.1% | — |
| 营业利润率 | 0.2% | — |
| 净利率 | -1.0% | — |
| 营收同比 | 2.0% | 19.6% |
| 净利润同比 | 92.4% | — |
| 每股收益（稀释后） | $-0.05 | $0.36 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXSFNC
| Q4 25 | $219.9M | $197.3M | ||
| Q3 25 | $205.6M | $186.7M | ||
| Q2 25 | $203.1M | $214.2M | ||
| Q1 25 | $193.6M | $209.6M | ||
| Q4 24 | $215.7M | $208.5M | ||
| Q3 24 | $196.6M | $174.8M | ||
| Q2 24 | $198.6M | $197.2M | ||
| Q1 24 | $188.6M | $195.1M |
净利润OFIXSFNC
| Q4 25 | $-2.2M | — | ||
| Q3 25 | $-22.8M | $-562.8M | ||
| Q2 25 | $-14.1M | $54.8M | ||
| Q1 25 | $-53.1M | $32.4M | ||
| Q4 24 | $-29.1M | — | ||
| Q3 24 | $-27.4M | $24.7M | ||
| Q2 24 | $-33.4M | $40.8M | ||
| Q1 24 | $-36.0M | $38.9M |
毛利率OFIXSFNC
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — | ||
| Q1 24 | 67.5% | — |
营业利润率OFIXSFNC
| Q4 25 | 0.2% | — | ||
| Q3 25 | -8.3% | — | ||
| Q2 25 | -7.9% | — | ||
| Q1 25 | -25.2% | — | ||
| Q4 24 | -5.3% | — | ||
| Q3 24 | -9.6% | — | ||
| Q2 24 | -12.5% | — | ||
| Q1 24 | -15.6% | — |
净利率OFIXSFNC
| Q4 25 | -1.0% | — | ||
| Q3 25 | -11.1% | -301.5% | ||
| Q2 25 | -6.9% | 25.6% | ||
| Q1 25 | -27.4% | 15.5% | ||
| Q4 24 | -13.5% | — | ||
| Q3 24 | -13.9% | 14.1% | ||
| Q2 24 | -16.8% | 20.7% | ||
| Q1 24 | -19.1% | 19.9% |
每股收益（稀释后）OFIXSFNC
| Q4 25 | $-0.05 | $0.36 | ||
| Q3 25 | $-0.57 | $-4.00 | ||
| Q2 25 | $-0.36 | $0.43 | ||
| Q1 25 | $-1.35 | $0.26 | ||
| Q4 24 | $-0.76 | $0.38 | ||
| Q3 24 | $-0.71 | $0.20 | ||
| Q2 24 | $-0.88 | $0.32 | ||
| Q1 24 | $-0.95 | $0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | — |
| 总债务越低越好 | — | $620.0M |
| 股东权益账面价值 | $450.0M | $3.4B |
| 总资产 | $850.6M | $24.5B |
| 负债/权益比越低杠杆越低 | — | 0.18× |
8季度趋势，按日历期对齐
现金及短期投资OFIXSFNC
| Q4 25 | $82.0M | — | ||
| Q3 25 | $62.9M | — | ||
| Q2 25 | $65.6M | — | ||
| Q1 25 | $58.0M | — | ||
| Q4 24 | $83.2M | — | ||
| Q3 24 | $30.1M | — | ||
| Q2 24 | $26.4M | — | ||
| Q1 24 | $27.0M | — |
总债务OFIXSFNC
| Q4 25 | — | $620.0M | ||
| Q3 25 | $157.2M | $667.8M | ||
| Q2 25 | $157.0M | $1.0B | ||
| Q1 25 | $156.9M | $1.3B | ||
| Q4 24 | $157.0M | $1.1B | ||
| Q3 24 | $118.5M | $1.4B | ||
| Q2 24 | $118.0M | $1.7B | ||
| Q1 24 | $118.2M | $1.2B |
股东权益OFIXSFNC
| Q4 25 | $450.0M | $3.4B | ||
| Q3 25 | $442.5M | $3.4B | ||
| Q2 25 | $458.3M | $3.5B | ||
| Q1 25 | $458.3M | $3.5B | ||
| Q4 24 | $503.1M | $3.5B | ||
| Q3 24 | $525.9M | $3.5B | ||
| Q2 24 | $546.0M | $3.5B | ||
| Q1 24 | $570.3M | $3.4B |
总资产OFIXSFNC
| Q4 25 | $850.6M | $24.5B | ||
| Q3 25 | $832.6M | $24.2B | ||
| Q2 25 | $837.2M | $26.7B | ||
| Q1 25 | $823.1M | $26.8B | ||
| Q4 24 | $893.3M | $26.9B | ||
| Q3 24 | $867.9M | $27.3B | ||
| Q2 24 | $882.0M | $27.4B | ||
| Q1 24 | $906.0M | $27.4B |
负债/权益比OFIXSFNC
| Q4 25 | — | 0.18× | ||
| Q3 25 | 0.36× | 0.20× | ||
| Q2 25 | 0.34× | 0.28× | ||
| Q1 25 | 0.34× | 0.35× | ||
| Q4 24 | 0.31× | 0.32× | ||
| Q3 24 | 0.23× | 0.40× | ||
| Q2 24 | 0.22× | 0.50× | ||
| Q1 24 | 0.21× | 0.36× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $449.5M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $411.4M |
| 自由现金流率自由现金流/营收 | 7.6% | 208.5% |
| 资本支出强度资本支出/营收 | 4.9% | 19.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $717.0M |
8季度趋势，按日历期对齐
经营现金流OFIXSFNC
| Q4 25 | $27.7M | $449.5M | ||
| Q3 25 | $12.4M | $223.4M | ||
| Q2 25 | $11.6M | $77.6M | ||
| Q1 25 | $-18.4M | $32.8M | ||
| Q4 24 | $23.7M | $425.9M | ||
| Q3 24 | $11.7M | $199.4M | ||
| Q2 24 | $9.0M | $86.1M | ||
| Q1 24 | $-18.6M | $57.6M |
自由现金流OFIXSFNC
| Q4 25 | $16.8M | $411.4M | ||
| Q3 25 | $2.5M | $216.7M | ||
| Q2 25 | $4.5M | $66.3M | ||
| Q1 25 | $-25.1M | $22.6M | ||
| Q4 24 | $15.2M | $380.4M | ||
| Q3 24 | $6.3M | $187.7M | ||
| Q2 24 | $-360.0K | $72.7M | ||
| Q1 24 | $-29.1M | $47.7M |
自由现金流率OFIXSFNC
| Q4 25 | 7.6% | 208.5% | ||
| Q3 25 | 1.2% | 116.1% | ||
| Q2 25 | 2.2% | 31.0% | ||
| Q1 25 | -13.0% | 10.8% | ||
| Q4 24 | 7.0% | 182.5% | ||
| Q3 24 | 3.2% | 107.4% | ||
| Q2 24 | -0.2% | 36.9% | ||
| Q1 24 | -15.4% | 24.5% |
资本支出强度OFIXSFNC
| Q4 25 | 4.9% | 19.3% | ||
| Q3 25 | 4.8% | 3.6% | ||
| Q2 25 | 3.5% | 5.3% | ||
| Q1 25 | 3.5% | 4.8% | ||
| Q4 24 | 4.0% | 21.8% | ||
| Q3 24 | 2.7% | 6.7% | ||
| Q2 24 | 4.7% | 6.8% | ||
| Q1 24 | 5.6% | 5.0% |
现金转化率OFIXSFNC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | — | 1.01× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 8.06× | ||
| Q2 24 | — | 2.11× | ||
| Q1 24 | — | 1.48× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
SFNC
暂无分部数据
